Welcome
Support Centre
09 January 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Neuragen® for the relief of neuropathic pain: a randomised, double-blind, placebo controlled clinical trial
ISRCTN ISRCTN13226601
ClinicalTrials.gov identifier
Public title Neuragen® for the relief of neuropathic pain: a randomised, double-blind, placebo controlled clinical trial
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis Neuragen® reduces neuropathic pain more and longer than placebo.
Ethics approval Ethics approval received from the Institutional Review Board of Louisiana State University as an extension of IRB#2754, approved on 28th September 2007.
Study design Randomised, double-blind, placebo controlled clinical trial
Countries of recruitment United States of America
Disease/condition/study domain Peripheral neuropathy
Participants - inclusion criteria 1. Male and female, over 21 years
2. Diagnosed neuropathic pain for more three months
3. Pain level between 3 - 8 on a 0 - 10 visual pain scale
4. Does not have mental and communication impairments
Participants - exclusion criteria 1. Pregnant
2. Have other types of pain
3. Skin condition
4. Central nerve impairment
Anticipated start date 01/01/2008
Anticipated end date 30/04/2008
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 60
Interventions Topical application of Neuragen® versus placebo. The medicine was sprayed onto the subjects feet at the sole and on top of the feet. One time application with an 8-hour follow-up.
Primary outcome measure(s) Foot sole pain on 11-point numerical pain scale. 0 - 10 visual analog scale was use to document pain level at 30 minutes before and after the administration of the medication, with 8-hour follow up every hour on the hour.
Secondary outcome measure(s) Duration of pain reduction. 0 - 10 visual analog scale was use to document pain level at 30 minutes before and after the administration of the medication, with 8-hour follow up every hour on the hour.
Sources of funding Origin BioMed, Inc. (Canada)
Trial website
Publications
Contact name Dr  Li  Li
  Address Department of Kinesiology
Louisiana State University
  City/town Baton Rouge
  Zip/Postcode 70803
  Country United States of America
Sponsor Origin BioMed, Inc. (Canada)
  Address 5162 Duke St, Suite 300
  City/town Halifax
  Zip/Postcode B3J 1N7
  Country Canada
  Sponsor website: http://originbiomed.com
Date applied 09/06/2008
Last edited 13/06/2008
Date ISRCTN assigned 13/06/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central